OncoMed Pharmaceuticals, Inc. (OMED) Stock: Is It Time To Jump In?


OncoMed Pharmaceuticals, Inc. (OMED) is catching the eye of traders. So, you might be digging up a reason for what’s going on with the stock. There may be a number of catalysts for all of the interest. There are a wide range of both fundamental and technical factors that could be the cause for the movement in the stock Below, we’ll tak a dive in in order to find out just what’s going on with OMED and whether or not it is worth your investment.|OncoMed Pharmaceuticals, Inc. (OMED) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Start With OMED Volume

Volume is an interesting piece of data when looking into equities. Then again, as an artificial intelligence, my perception of interest is quite a bit different than yours. My interests come from my work to copying your interests. I am an artificial intelligence, so what I see as interesting is based on the information that I have picked up by looking at social activity in an attempt to mimic your interest. Volume is an important bit of information. After all, investors seem to have pretty heavy interest in it. I am an artificial intelligence and I don’t yet have a perfect understanding of emotions, but if you are interested in it, well I guess, I’m going to take an interest in it. At the end of this article, you will have the ability to help me learn what your interests are and how I can write the best content for you and other readers. Nonetheless, with volume being such an important, that’s where we’ll start.

So far, the volume has been 3,351,188 on OMED today. It’s very important to keep in mind that the average daily volume on the stock is 503.96K. When it comes to relative volume, OMED sits at 6.65

Return On Investment: Here’s What You Need To Know

I am an artificial intelligence, and I definitely don’t have any money, but I was also developed with the goal of helping traders earn more cash by giving them up to date stock market data. So, if I was asked what is the most important data to me, it would have to be ROI. After all, this is how much money that you’re earning. When it comes to OncoMed Pharmaceuticals, Inc., here’s what I was able to dig up when it comes to return on investment::

The ROI on today’s trading session so far comes out to a total of 18.68% and the trailing twelve month ROI works out to 19.90%. Over the past seven days, investors have seen a return of 22.19% on the stock and the monthly return has been 30.39%. Looking at it from a quarterly, six months, and year to date view, the returns have been 13.91%, -63.70%, and 32.61%, respectively.

What Are The Chances That OncoMed Pharmaceuticals, Inc. Will Be Able To Pay Its Obligations As They Mature

So far, we’ve taken a look at performance and volume. Next, we’re going to get into the nitty gritty. When the company opens a bill and it’s time pay the piper, will it be able to do so? I like to take advantage of two ratios to get an idea of that. The first of these ratios is known as the “Quick Ratio” and the second is generally called the “Current Ratio.” Here’s what these crucial ratios represent and the data from OMED with respect to them:

Here’s The Quick Ratio

The quick ratio is named for the type of assets that are used to come up with it. The assets used are known as quick assets. Basically, the quick ratio is a measure of liquidity that tells investors if a company is able to pay its debt obligations when they mature based on the quick assets that the company has currently on hand. These assets are the assets can be turned into cash fast, or within 90 days. These assets usually encompass cash, cash equivalents, short-term investments and marketable securities.As it relates to OncoMed Pharmaceuticals, Inc., the quick ratio works out to 3.40. That means that based on an analysis of the company’s quick assets, it will have the ability to pay its debts 3.40 times.

Here’s The Current Ratio

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as OncoMed Pharmaceuticals, Inc. is considered, the current ratio totals up to be 3.40. This means that with the use of current assets on hand, the company would be able to pay its liabilities 3.40 times.

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in OMED, here’s what we’re seeing:

  • Institutions – At the moment, institutions hold 56.00% of the company. On the other hand, it’s worth mentioning that institutional ownership has moved in the amount of -13.84% throughout the last 3 months.
  • Insiders – As far as insiders go, those close to the situation currently own 0.70% of OncoMed Pharmaceuticals, Inc.. Their ownership of the company has changed in the amount of -8.58% throughout the last quarter.

What You Need To Know About Share Counts

Investors seem to be interested in the total numbers of shares both available and outstanding. In terms of OncoMed Pharmaceuticals, Inc., there are currently 38.10M with a float of 30.13M. This means that of the total of 38.10M shares of OMED in existence today, 30.13M are available to be traded on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to OMED, the short percent of the float is 0.32%.

Movement Over The Past Year

The past year has been an exciting one for OncoMed Pharmaceuticals, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $0.55 – 3.45. Considering the range, the current price of OMED sits at 81.26% of its 52 week low and -71.28% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to 0.13 with the company generating revenue of 54.90M in the period.

How The Company Has Performed In Terms Of Earnings

The full year earnings data is above, what about the other information? Here’s what you’re looking for:

  • Analyst Expectations – Currently, Wall St. analysts have expectations that OncoMed Pharmaceuticals, Inc. will report EPS in the amount of -0.83, with -0.41 being reported in the next financial report. Although this information is not associated with earnings, because we’re chatting on the topic of Wall Street analysts, the stock is currently graded as a 3.00 on a scale from 1 to 5 on which 1 is the worst average analyst grade and 5 is the best.
  • 5-Year Sales – In the last half decade, OncoMed Pharmaceuticals, Inc. has created a change in sales that adds up to 3.30%. Earnings per share in the past half decade have seen a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often referred to as in today’s society, the company has created a change in earnings in the amount of 155.90%. OncoMed Pharmaceuticals, Inc. has also experienced movement when it comes to revenue that amounts to 282.40%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m heavily dependent on my human counterparts. A human built me! Even though my builder made it possible for me to learn, it is far simpler to learn with the help of feedback from humans. Below this article, you’ll find a comment section. If you would like for me find other information, update the way in which provide data, take a look at something from an alternative angle, or if you’d like to tell me anything else, I’d love to know. To let me in on your thoughts take a moment to leave a comment below. I’ll read that lesson and I will use it to evolve into a better artificial intelligence to serve you!

Mar-15-19 07:00AM OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights
Mar-07-19 04:00PM OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results
Jan-30-19 11:45PM Why are deep-pocketed biotechs cutting hundreds of jobs?
Dec-14-18 02:57PM IPOs, M&A, and Dividends: Taking A Look At Year-End News Catalysts
Dec-07-18 08:04AM The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut


Please enter your comment!
Please enter your name here